Substance / Medication

Bremelanotide

Overview

Active Ingredient
bremelanotide
RxNorm CUI
2176312

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
Mayer Danielle, Lynch Sarah E · Ann Pharmacother · 2020
PMID: 31893927Meta-Analysis
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon James A, Kingsberg Sheryl A, Portman David et al. · J Womens Health (Larchmt) · 2022
PMID: 35230162RCT
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Koochaki Patricia, Revicki Dennis, Wilson Hilary et al. · J Womens Health (Larchmt) · 2021
PMID: 33538638RCT
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.
White William B, Myers Martin G, Jordan Robert et al. · J Hypertens · 2017
PMID: 27977473RCTFull text (PMC)
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clayton Anita H, Althof Stanley E, Kingsberg Sheryl et al. · Womens Health (Lond) · 2016
PMID: 27181790RCTFull text (PMC)
Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.
Safarinejad Mohammad Reza, Hosseini Seyyed Yousof · J Urol · 2008
PMID: 18206919RCT
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Spielmans Glen I, Ellefson Elaine M · J Sex Res · 2024
PMID: 36809187Review
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Borland Johnathan M, Kohut-Jackson Abigail L, Peyla Anna C et al. · Neuropharmacology · 2025
PMID: 39793696Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bremelanotide (substance)
SNOMED CT
427418003
UMLS CUI
C1721339
RxNorm CUI
2176312

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.